Program
PF-07868489
A development code.
Its studies are mostly in Hypertension, Pulmonary · Pulmonary Arterial Hypertension, led by Pfizer.
Furthest: phase 2, since Nov 14, 20232 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 20 open or running | phase 2since Nov 14, 2023 | Nov 14, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2023First study: phase 2 study in Pulmonary Arterial HypertensionFirst studyNCT06137742 · 97 enrolled · United States, Australia, Belgium and more
- Jul 9, 2025Phase 2 study in Hypertension, PulmonaryNCT07073820 · 42 enrolled · United States, Australia, Belgium and more
- Nov 2, 2026Phase 2 study terminatedStudy stoppedNCT07073820 · “The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.”
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07073820Hypertension, Pulmonary · United States, Australia, Belgium and more | 2 | Terminated | Oct 9, 2026 | 42 |
| NCT06137742Pulmonary Arterial Hypertension · United States, Australia, Belgium and more | 2 | Completed | Jul 31, 2026 | 97 |
How it is read
Names in the registry
- “PF-07868489”, 2 entries
Codes read as this program: PF07868489.
Conditions, from the studies’ own filings
- Hypertension, Pulmonary, 1 study
- Pulmonary Arterial Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.